Why Probe Dose Is a Design Choice
A probe substrate can be sensitive and selective for a pathway yet still be used at an unsuitable dose. If the dose is too low, concentrations may be difficult to quantify and exposure estimates may be imprecise. If it is too high, safety limits may be approached, or the probe may engage concentration-dependent processes that make the measured interaction depend on the dose itself. Probe dose selection therefore balances measurability, safety, and interpretable pharmacokinetics.
The aim is not automatically to use the lowest possible dose or the largest tolerated dose. It is to choose a dose for which the probe produces a reliable exposure signal, remains within acceptable safety limits, and samples the disposition pathways under conditions relevant to the interaction question. The introductory material on choosing sensitive and selective probe substrates addresses which substrate is informative; here the focus is the amount administered.
Start With the Exposure and Safety Constraints
A practical dose assessment begins with candidate doses and predicted exposure in both the control condition and the anticipated DDI condition. The inhibitor or inducer may alter probe exposure, so a dose that appears safe without the perpetrator may not satisfy the same constraint during the interaction. Conversely, a low control exposure may become readily measurable under inhibition. Use the more restrictive plausible condition for each constraint.
For a drug with linear pharmacokinetics over the candidate range, bioavailability \(F\) and clearance \(CL\) do not change materially with dose. Under that assumption, total exposure is approximately dose proportional:
Here \(D\) is dose and \(AUC\) is the area under the plasma concentration-time curve. If the concentration profile scales proportionally, \(C_{\max}\) also scales with dose. These relationships are useful for screening candidate doses, but they are assumptions to check, not guarantees. Changes in absorption, first-pass availability, binding, metabolism, or transport can break dose proportionality.
Assay capability should be expressed in terms of the actual endpoint and sampling context. For example, a predicted \(C_{\max}\) well above the lower limit of quantification (LLOQ) is reassuring, but it does not by itself prove that later concentrations used to characterize exposure will be quantifiable. Safety constraints likewise should use protocol-defined limits, the drug's known safety information, and predicted exposure under the relevant conditions; an exposure threshold should not be invented from a mathematical model alone.
Worked Example: Finding a Dose Range From Measurability and Safety Bounds
Suppose a hypothetical probe has a predicted \(C_{\max}\) of 12 ng/mL after a 4 mg dose. Assume dose-proportional pharmacokinetics over the candidate range. For this illustration, the assay criterion is a predicted \(C_{\max}\) of at least 0.6 ng/mL, and a protocol-defined safety review sets an upper predicted \(C_{\max}\) of 18 ng/mL. Find the dose range meeting both criteria, then evaluate a 2 mg candidate.
Under dose proportionality, the predicted peak concentration per milligram is \(12/4=3\) ng/mL per mg. Thus, for dose \(D\) in mg, the predicted peak is \(C_{\max}=3D\) ng/mL.
The measurability criterion requires \(3D\geq0.6\), so \(D\geq0.20\) mg. The safety criterion requires \(3D\leq18\), so \(D\leq6.0\) mg. The resulting screening interval is 0.20 to 6.0 mg, subject to the assumptions and to any other clinical constraints.
At 2 mg, \(C_{\max}=3(2)=6.0\) ng/mL. That is ten times the illustrative assay threshold and below the illustrative upper limit. The calculation identifies a feasible candidate, not a final clinical dose: other exposure endpoints, the DDI condition, and the safety assessment still matter.
Check Whether the Candidate Dose Changes the Kinetics
A key concern is saturation of a process that contributes to probe disposition. For Michaelis-Menten elimination, the elimination rate at concentration \(C\) is
where \(V_{\max}\) is the maximum elimination rate and \(K_m\) is the concentration at which the rate is half of \(V_{\max}\). At concentrations far below \(K_m\), the rate is approximately proportional to concentration. As concentration approaches or exceeds \(K_m\), the rate becomes less than proportional. The same general issue can arise in saturable uptake, efflux, metabolism, or absorption.
A useful descriptive measure of saturation for this equation is the fraction of \(V_{\max}\) reached, \(C/(K_m+C)\). A maximum acceptable fraction is a modeling or study-planning criterion, not a universal clinical rule. For example, if a project specifies that this fraction should be no more than 10%, then:
The concentration used for this assessment should represent the relevant enzyme or transporter site as well as possible. Plasma total concentration may be a poor surrogate when the local unbound concentration differs substantially. A PBPK model can help estimate concentrations at the site, but the result inherits uncertainty in tissue partitioning, binding, transport, and pathway parameters. Consider the predicted range across plausible parameter values, not only a single nominal simulation.
Evaluate the saturation criterion in both control and DDI conditions. Inhibition of a clearance pathway can raise probe concentrations, potentially moving the probe into a more saturated range even when the control condition is approximately linear. This can alter the exposure ratio and complicate interpretation. A dose should not be accepted as “nonsaturating” solely because the control-condition concentration is low.
Worked Example: Applying a Site-Saturation Criterion in Both Conditions
In a hypothetical PBPK simulation, a 10 mg probe dose produces a maximum unbound concentration of 0.40 µmol/L at a relevant elimination site in the control condition. The model predicts a twofold increase in that concentration during inhibition. Assume \(K_m=4.0\) µmol/L and a prespecified screening criterion that no more than 10% of \(V_{\max}\) should be reached. Candidate-dose concentrations are assumed to scale proportionally for this comparison.
At 10 mg, the predicted concentration during inhibition is \(2(0.40)=0.80\) µmol/L. The saturation fraction is \(0.80/(4.0+0.80)=0.1667\), or 16.7%. This exceeds the 10% criterion.
For a 5 mg dose, proportional scaling gives a control concentration of 0.20 µmol/L and an inhibited-condition concentration of 0.40 µmol/L. The latter gives a saturation fraction of \(0.40/(4.0+0.40)=0.0909\), or 9.09%. It meets the illustrative criterion in both conditions; the inhibited condition is the limiting one.
This result supports considering 5 mg rather than 10 mg, but it does not establish that 5 mg is suitable overall. Its exposure must still be quantifiable, other pathways and safety constraints must be checked, and uncertainty in local concentrations and \(K_m\) must be considered. The assumed proportional scaling should also be verified rather than extended beyond its supported range.
Use Dose Proportionality as a Diagnostic, Not a Verdict
Dose proportionality can be assessed using prior data, a carefully justified model, or dose-ranging observations when available. Under proportional pharmacokinetics, doubling the dose should approximately double \(AUC\) and \(C_{\max}\), and dose-normalized values such as \(AUC/D\) should be similar across doses. Systematic departures may indicate nonlinear pharmacokinetics, but observed differences can also reflect variability, study conditions, or measurement error. A departure is a signal to investigate, not proof of a particular mechanism.
Worked Example: Detecting a Departure From Dose Proportionality
Consider hypothetical dose-ranging data for a probe. After 1 mg, the observed \(AUC\) is 20 mg·h/L; after 2 mg, it is 48 mg·h/L; and after 4 mg, it is 128 mg·h/L. Compare dose-normalized exposure.
The values of \(AUC/D\) are \(20/1=20\), \(48/2=24\), and \(128/4=32\) h/L. If exposure were dose proportional, the \(AUC\) after 4 mg would be four times the 1 mg value, or \(4(20)=80\) mg·h/L. The observed 128 mg·h/L is 1.60 times that value.
These data show a pattern consistent with greater-than-proportional exposure across the tested range. Possible explanations include saturable elimination or dose-dependent absorption, but these observations alone do not identify the cause. For a DDI study intended to characterize pathway inhibition, using a higher dose without investigating the pattern could make the estimated interaction dependent on probe dose. A lower candidate dose may be preferable if it remains quantifiable and meets safety requirements.
A Practical Selection Sequence
Specify assay capability, relevant exposure endpoints, protocol safety limits, and the pathway-concentration range needed for an interpretable interaction assessment.
Predict exposure with and without the perpetrator, using the intended clinical conditions and a model supported by available data.
Check predicted concentrations at relevant sites against pathway kinetics, and compare dose-normalized exposure across available doses or simulations.
Vary influential parameters and examine whether the candidate remains measurable, safe, and below the chosen saturation criterion under plausible scenarios.
Choose a dose within the feasible region and document which constraint is limiting, what assumptions support the choice, and what uncertainty remains.
Alternatives, Diagnostics, and Limitations
A microdose can reduce exposure and may be useful when safety or pathway saturation is a concern. Its limitation is that the resulting concentrations may be difficult to quantify, and microdose behavior may not predict behavior at higher concentrations if absorption, transport, or metabolism is nonlinear. A low therapeutic or subtherapeutic dose may improve measurability while keeping concentrations in a relatively linear range, but it still requires safety review and model-based assessment. A higher dose may improve assay signal, yet can introduce saturation, dose-dependent bioavailability, or safety concerns. No option is universally preferable.
Warning signs include dose-normalized \(AUC\) or \(C_{\max}\) that changes systematically with dose; predicted concentrations near or above a relevant \(K_m\); a large difference between control and DDI concentrations relative to the saturation threshold; and simulated exposure that is highly sensitive to poorly known parameters. Apparent contradictions between clinical dose-ranging data and PBPK predictions also require investigation. Check assumptions about formulation, food, binding, absorption, and pathway contributions before attributing a mismatch to saturation.
A common mistake is to select the highest dose that remains below a toxicity limit and assume that the resulting exposure ratio is therefore maximally informative. Safety is necessary but not sufficient: a high dose may saturate the very process whose inhibition is being measured, changing the interaction ratio. The correction is to evaluate quantifiability, safety, and pathway linearity together, including predicted exposure during the DDI condition.
Dose selection remains conditional on the available evidence. PBPK predictions do not remove uncertainty in model structure or parameters, and a chosen saturation threshold is a practical criterion rather than proof that dose effects are absent. The final choice should be supported by the full evidence set and appropriate clinical and ethical review.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- Under dose-proportional pharmacokinetics, a 3 mg dose gives \(C_{\max}=9\) ng/mL. What \(C_{\max}\) is predicted at 1 mg, and what assumption supports the calculation?
- For Michaelis-Menten elimination, what is the fraction of \(V_{\max}\) reached at \(C=K_m\)?
- A dose is below a safety limit in the control condition but exceeds a site-saturation criterion during predicted inhibition. Is it suitable on those results alone? Explain.
- What does an increasing \(AUC/D\) across dose levels suggest, and what can it not establish by itself?
Solutions. (1) \(9(1/3)=3\) ng/mL, assuming \(C_{\max}\) scales proportionally with dose over that range. (2) \(K_m/(K_m+K_m)=1/2\), or 50% of \(V_{\max}\). (3) No. The DDI condition must also meet the relevant constraints; the predicted increase may place the probe in a concentration-dependent range. (4) It suggests greater-than-proportional exposure over the observed range, but does not identify the mechanism or rule out variability and measurement error.